These patients struggle with runaway bones. Finally there’s hope

The FDA approved two new treatments for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. Regeneron's garetosmab (Pasatru) and Mirum's zilurgisertib (Atebrioz) reduce abnormal bone growth. FOP affects about 900 people worldwide, with limited mobility and shortened lifespans. Trials for pediatric use are ongoing.

Original reporting
Published Nov 21, 2026, 3:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 21, 2026, 8:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
These patients struggle with runaway bones. Finally there’s hope — source image
Decision brief

The 30-second read

$REGNBullishMed
01

Why it matters

Regeneron's approval introduces a novel therapy for a disease with no prior treatments, potentially driving stock appreciation and encouraging further investment in rare‑disease pipelines.

02

Market read

New FDA approvals for rare‑disease drugs provide a clear catalyst for Regeneron and signal broader biotech sector momentum.

03

What to watch

Limited patient pool (≈900 cases) may cap revenue, and reimbursement uncertainty could dampen impact.

Relevance 7/10Novelty 9/10Timing: post‑approval

Background

The article describes recent FDA approvals of two drugs for the ultra‑rare disease FOP: garetosmab by Regeneron and zilurgisertib by Mirum, and discusses patient stories and scientific background.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

FDA approved garetosmab (Pasatru), a monoclonal antibody made by Regeneron for adults with fibrodysplasia ossificans progressiva (FOP).

Expected impact

likely upward pressure as investors price in the new indication.

Evidence & confidence

First‑time FDA approval for a rare disease drug provides a clear revenue opportunity and validates Regeneron's R&D pipeline.

Market effects

Boosts biotech and rare‑disease therapeutic sector as investors see new FDA approvals as catalyst.

Positive for US biotech equities and related ETFs.

Highlights potential for similar rare‑disease treatments worldwide.

Counterpoint

Approval may be priced in already; market could be disappointed if sales ramp slower than expected.

Key entities

  • Regeneron Pharmaceuticals

    US biotech company that received FDA approval for garetosmab.

  • Mirum Pharmaceuticals

    Biotech firm that received FDA approval for zilurgisertib.

  • FDA

    U.S. Food and Drug Administration that granted the approvals.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.

$REGNMed

REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals received FDA approval for Livsayis, a siRNA therapy for generalized myasthenia gravis (gMG). It is the first of its kind and is administered subcutaneously four times a year. The approval was based on positive phase III NIMBLE study results, showing significant symptom improvement. Livsayis carries a Boxed Warning for serious infections. Regeneron's stock has risen 22.9% year-to-date. The therapy is under review in the EU and planned for other regions.